Christopher Aker - 12 Jan 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Signature
Christopher Aker
Issuer symbol
RGLS
Transactions as of
12 Jan 2024
Net transactions value
$0
Form type
4
Filing time
17 Jan 2024, 17:04:34 UTC
Previous filing
14 Aug 2023
Next filing
18 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Award $0 +11,250 +263% $0.000000 15,524 12 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +70,000 $0.000000 70,000 12 Jan 2024 Common Stock 70,000 $1.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 11, 2023, the reporting person was granted Restricted Stock Units (RSUs). The RSUs only vested upon achievement of a performance-based milestone. The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant. The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus.
F2 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.